SDP01873 / Jiangsu Hengrui Pharma - LARVOL DELTA

SDP01873, a novel HER3×c-Met bispecific antibody-drug conjugate (ADC) targeting EGFR tyrosine kinase inhibitor (TKI)-resistant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and beyond (AACR 2025) - "SDP01873 showed higher internalization activity than the HER3 ADC, U3-1402 analog (synthesized in-house), indicating an augment to internalization activity through dual targeting. SDP01873 represents a novel HER3×c-Met ADC with superior internalization activity and higher anti-tumor activity in preclinical models of NSCLC and CRC, and efficacy in PDX models resistant to EGFR TKI was also observed. The promising preclinical data support its advancing into clinical testing, and an Investigational New Drug (IND) application to NMPA has been approved in 2024."

Late-breaking abstract • Colorectal Cancer • Gastric Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • ERBB3 • MET